UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON D. C. 20549


                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES ANDEXCHANGE ACT OF 1934.


                                OCTOBER 25, 2005
                Date of Report (Date of Earliest Event Reported)


                             DNAPRINT GENOMICS, INC.
               --------------------------------------------------
               (Exact name of Registrant as specified in charter)


                         COMMISSION FILE NUMBER: 0-31905


         UTAH                                                  59-2780520
------------------------                               -------------------------
(State of Incorporation)                               (I.R.S. Employer I.D. No)



                     900 COCOANUT AVENUE, SARASOTA, FL 34236
                    ----------------------------------------
                    (Address of Principal Executive Offices)


                                 (941) 366-3400
              ----------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)


      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

      |_|   Written communications pursuant to Rule 425 under the Securities Act
            (17 CFR 230.425)

      |_|   Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
            (17 CFR 240.14a-12)

      |_|   Pre-commencement  communications pursuant to Rule 14d-2(b) under the
            Exchange Act (17 CFR 240.14d-2(b))

      |_|   Pre-commencement  communications pursuant to Rule 13e-4(c) under the
            Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

ITEM 1.01   ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

License Agreement with Dr. Mark Froimowitz
------------------------------------------

      On October 25, 2005, the Registrant,  through its wholly owned subsidiary,
DNAPrint  Pharmaceuticals,  Inc. entered into an exclusive  Licensing  Agreement
(the "License") with Dr. Mark Froimowitz to develop a series of  methylphenidate
analogs or Ritalin-like compounds targeting the clinical development of enhanced
pharmaceuticals   for  the  treatment  of  drug  addiction,   attention  deficit
hyperactivity  disorder  ("ADHD"),  and depression.  The licensed  compounds are
analogs of Ritalin,  a well-known  drug used for treatment of ADHD.  The analogs
are designed  specifically  to have a slow onset and increased  half-life in the
bloodstream,  thus reducing a patient's  required daily dosage and the potential
for drug abuse.  The Registrant has the exclusive right to develop,  use, market
and sell products derived from the licensed compounds.

      The  Registrant  is  obligated  to pay the  Licensor  a two  percent  (2%)
quarterly  royalty  fee on the net sales of  products  covered  by the  License.
Minimum  annual  maintenance  fees of $25,000 are required for the License term,
but will be deducted from royalties. Additionally, the License requires progress
payments of up to  $275,000  upon the  successful  development  and  approval of
licensed  products.  The License's initial five (5) year term is supplemented by
options capable of extending the License term for up to twenty years.

ITEM 2.03   CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN
OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

      See Item 1.01 above.


                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                         DNAPrint genomics, Inc.


                                         By: /s/ Richard Gabriel
                                             -----------------------------------
                                             Richard Gabriel, President
{"company-data": {"conformed-name": "DNAPRINT GENOMICS INC", "cik": "0001127354", "assigned-sic": "8731", "irs-number": "592780520", "state-of-incorporation": "UT", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-31905", "film-number": "051166628"}, "business-address": {"street1": "900 COCONUT AVE.", "city": "SARASOTA", "state": "FL", "zip": "34231", "phone": "9413663400"}, "mail-address": {"street1": "900 COCOANUT AVENUE", "street2": "NO SUITE", "city": "SARASOTA", "state": "FL", "zip": "34231"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON D. C. 20549

                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES ANDEXCHANGE ACT OF 1934.

                                OCTOBER 25, 2005
                Date of Report (Date of Earliest Event Reported)

                             DNAPRINT GENOMICS, INC.
               --------------------------------------------------
               (Exact name of Registrant as specified in charter)

                         COMMISSION FILE NUMBER: 0-31905

         UTAH                                                  59-2780520
------------------------                               -------------------------
(State of Incorporation)                               (I.R.S. Employer I.D. No)

                     900 COCOANUT AVENUE, SARASOTA, FL 34236
                    ----------------------------------------
                    (Address of Principal Executive Offices)

                                 (941) 366-3400
              ----------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)

      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

      |_|   Written communications pursuant to Rule 425 under the Securities Act
            (17 CFR 230.425)

      |_|   Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
            (17 CFR 240.14a-12)

      |_|   Pre-commencement  communications pursuant to Rule 14d-2(b) under the
            Exchange Act (17 CFR 240.14d-2(b))

      |_|   Pre-commencement  communications pursuant to Rule 13e-4(c) under the
            Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01   ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

License Agreement with Dr. Mark Froimowitz
------------------------------------------

      On October 25, 2005, the Registrant,  through its wholly owned subsidiary,
DNAPrint  Pharmaceuticals,  Inc. entered into an exclusive  Licensing  Agreement
(the "License") with Dr. Mark Froimowitz to develop a series of  methylphenidate
analogs or Ritalin-like compounds targeting the clinical development of enhanced
pharmaceuticals   for  the  treatment  of  drug  addiction,   attention  deficit
hyperactivity  disorder  ("ADHD"),  and depression.  The licensed  compounds are
analogs of Ritalin,  a well-known  drug used for treatment of ADHD.  The analogs
are designed  specifically  to have a slow onset and increased  half-life in the
bloodstream,  thus reducing a patient's  required daily dosage and the potential
for drug abuse.  The Registrant has the exclusive right to develop,  use, market
and sell products derived from the licensed compounds.

      The  Registrant  is  obligated  to pay the  Licensor  a two  percent  (2%)
quarterly  royalty  fee on the net sales of  products  covered  by the  License.
Minimum  annual  maintenance  fees of $25,000 are required for the License term,
but will be deducted from royalties. Additionally, the License requires progress
payments of up to  $275,000  upon the  successful  development  and  approval of
licensed  products.  The License's initial five (5) year term is supplemented by
options capable of extending the License term for up to twenty years.

ITEM 2.03   CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN
OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

      See Item 1.01 above.

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                         DNAPrint genomics, Inc.

                                         By: /s/ Richard Gabriel
                                             -----------------------------------
                                             Richard Gabriel, President